Insights

Nine European companies and research institutes combine forces in the NanoPilot-project to create a pilot plant aimed at accelerating the development of nanomedicine by facilitating the production of small clinical batches under Good Manufacturing Practice (GMP). One of the first three nanopharmaceuticals chosen for production in the pilot plant is a promising intranasal HIV vaccine.

Column in Kauppalehti by Pekka Koponen, May, 2014

Spinverse will team with eight European companies and research institutes in the EU-funded research and innovation project “IP4Plasma” in an effort to fight the second biggest killer among infectious diseases. The aim is to produce a highly sensitive tuberculosis test that will allow a diagnosis within minutes with costs as low as 1€ per test.